Personalized T-Cell therapy takes on advanced lung cancer
NCT ID NCT07673419
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This early-stage trial tests a new cell therapy called GK01 for people with advanced lung cancer who have not responded to standard treatments. The therapy uses a patient's own immune cells (T cells) that are specially prepared to attack the cancer. The main goal is to check safety, but researchers will also look for signs that the treatment shrinks tumors or controls the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GK01 cell injection (autologous tumor-reactive T cells)
What this could lead to
If successful, this could offer a new treatment option for people with advanced lung cancer who have run out of standard therapies.
What could go wrong
This is a very early, small trial (10 people) focused on safety. The treatment may not shrink tumors or may cause serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University Cancer Hospital
Beijing, China
-
Peking University Cancer Hospital
Beijing, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••